Charuwan Akewanlop

6PUBLICATIONS
22CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical biochemistry - lipids
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 22, 2026
Real World Evidence of Clinical Outcomes of First-Line Chemotherapy in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Patients.

Nunticha Umpawan, Panotpol Termsinsuk, Uayporn Kaosombatwattana

|Oct 28, 2023
Cost-Utility and Budget Impact Analyses of Oral Chemotherapy for Stage III Colorectal Cancer: Real-World Evidence after Policy Implementation in Thailand.

Pochamana Phisalprapa, Chayanis Kositamongkol, Krittiya Korphaisarn

|Jan 31, 2023
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

Roy S Herbst, Yi-Long Wu, Thomas John

|Jun 13, 2022
Low Fat-Free Mass Index Measured by Bioelectrical Impedance Analysis Correlates With Hematologic Adverse Events in Early-Stage Breast Cancer Patients Receiving Chemotherapy: A Prospective Observational Cohort Study.

Jirawat Thanestada, Varalak Srinonprasert, Akarin Nimmannit

|Jan 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.

Margarita Majem, Jonathan W Goldman, Thomas John

|Jun 23, 2021
Loss of CDX-2 expression is an independent poor prognostic biomarker in patients with early-stage deficient mismatch repair colorectal cancer.

Krittiya Korphaisarn, Kanjana Sukhokanjanachusak, Ananya Pongpaibul

Pageof 1

Frequent Collaborators

3 joint publications

Krittiya Korphaisarn

2 joint publications

Jonathan W Goldman

2 joint publications

Terufumi Kato

2 joint publications

Huu Vinh Vu